For CME Information & Credit Visit: https://www.iridiumce.com/leveling-up-pbc-podcast-2

Summary:
This conversation delves into the management of Primary Biliary Cholangitis (PBC), focusing on the role of biomarkers in treatment, the impact of pruritus on patients' quality of life, and the latest strategies for managing this condition. The discussion highlights the importance of effective monitoring and treatment options, as well as the need for new therapies to address the challenges faced by patients with PBC.

Takeaways:

• Biomarkers are crucial for monitoring PBC progression.
• Alkaline phosphatase and bilirubin are key indicators.
• UDCA is the first-line treatment for PBC.
• Pruritus affects up to 75% of PBC patients.
• Antihistamines are ineffective for PBC-related pruritus.
• Colestyramine is the first-line therapy for pruritus.
• New therapies for pruritus are in development.
• Patient quality of life is significantly impacted by pruritus.
• Real-world evidence shows under-treatment of pruritus.
• Effective management strategies are essential for patient adherence.

Sound Bites:

• "Biomarkers play a key role in the management of PBC."
• "Pruritus significantly impacts the lives of patients with PBC."
• "Antihistamines are not effective for PBC-related pruritus."

For CME Information & Credit Visit: https://www.iridiumce.com/mastering-the-complexity-of-aml-tx-podcast-1

Summary:

This conversation explores the complexities of Acute Myeloid Leukemia (AML) treatment, focusing on advancements in diagnosis, the importance of timely treatment, understanding remission and measurable residual disease (MRD), and the evolving strategies in treatment decision-making. Dr. Courtney DiNardo discusses the significance of genetic and cytogenetic factors in guiding therapy and emphasizes the need for personalized approaches in patient care.

Takeaways:

• AML treatment has seen significant advancements in the last decade.
• Timely diagnosis and treatment initiation are crucial for patient outcomes.
• Understanding different types of remission is essential for treatment planning.
• MRD status is a key indicator of treatment success and relapse risk.
• Genetic testing plays a vital role in determining the best treatment options.
• Transplant considerations should be made early in the treatment process.
• Patient goals and preferences should guide treatment decisions.
• Age alone should not dictate treatment intensity; comorbidities matter.
• Sequential MRD testing is more beneficial than a one-time assessment.
• Future guidelines will increasingly rely on molecular and cytogenetic biomarkers.

Sound Bites:

• "Mastering the Complexity of AML Treatment"
• "12 new approvals for different AML patient populations"
• "We want to get the information back quickly"

For CME Information & Credit Visit: https://www.iridiumce.com/leveling-up-pbc-podcast-1

Summary:

This conversation focuses on Primary Biliary Cholangitis (PBC), discussing its diagnosis, differentiation from other liver diseases, and evolving treatment paradigms. The speakers emphasize the importance of personalized care and a multidisciplinary approach to manage the systemic complications associated with PBC. They also explore a real-world case study to illustrate the application of these principles in patient management.

Takeaways:

• PBC is diagnosed through serologic tests and imaging.
• Differentiating PBC from other liver diseases is crucial.
• Current treatment involves UDCA, but many patients are unresponsive.
• New treatment paradigms focus on personalized care.
• Multidisciplinary teams are essential for managing PBC complications.
• Obetacolic acid and L-epipneuronal are new treatment options.
• Patient compliance with medication is critical for treatment success.
• Systemic complications of PBC include osteoporosis and vitamin deficiencies.
• Challenges in PBC management include physician awareness and patient education.
• Personalized care can enhance patient outcomes in PBC management.

Sound Bites:

• "PBC is fairly straightforward to diagnose."
• "The current paradigm is once you diagnose PBC."
• "The new paradigm is more of a personalized care."